Lymphokine Activated Killer (LAK) Cells Inhibit the in vitro Growth of Myeloid and Erythroid Progenitor Cells Via the Release of Tumor Necrosis Factor-Alphadagger.

Abstract

Adoptive immunotherapy with lymphokine-activated killer (LAK) cells induced by Interleukin 2 (IL2) has provided a new and promising strategy for the treatment of cancer patients. The clinical observation of variable degrees of cytopenia(s) in patients with solid tumors treated with LAK cells suggests that IL2-activated effector cells may play a role on the… (More)
DOI: 10.1080/10428199009169604

Topics

  • Presentations referencing similar topics